Gastrointestinal biotech AzurRX Biopharma decreases proposed IPO deal size

AzurRX Biopharma(IPO), which is developing non-systemic biologics for gastrointestinal disorders, again lowered the proposed deal size for its upcoming IPO on Wednesday.

The Brooklyn, NY-based company now plans to raise $6.6 million by offering 1.2 million shares at a price of $5.50. The company had previously filed to offer 1.7 million shares at a range of $6 to $8, and before that had originally filed to offer 2.1 million shares at the same price. At $5.50, AzurRX Biopharma IPO will raise -45% less in proceeds than previously anticipated. 

New IPO of AzurRX Biopharma was founded in 2007 and plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities are the joint bookrunners on the deal. A pricing date has not yet been disclosed. renaissancecapital

Also Read :

After Mexico IPOs Dwindle, Two Companies Try to Buck Slump

Big IPO, small splash: China bank PSBC fails to make waves after $7.4b HK debut

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.